EUVIMEDEUVIMED entdecken
Crossref

Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN ‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg ‐Positive Chronic Hepatitis B Patients

Jiaxuan Chen iD, Jia Hou iD, Rong Na iD, Bin Zhou iD, Jinlin Hou iD, De-Ke Jiang iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Jiaxuan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Departme…. Hauptthemen laut MEDLINE: Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously reported that an interferon (IFN)‐inducible protein, BST2, was regulated by the JAK–STAT pathway activated by CD40, and subsequently suppressing hepatitis B virus (HBV) repliaction and transcription. The current research attempted to assess the impact of BST2 on the IFN‐treated anti‐HBV effect, and explore BST2 variants for predicting pegylated IFN alpha (PegIFNα) therapy response of patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB). Using an HBV‐transfected cell model, the function of BST2 on HBV DNA replication and transcription driven by IFN was studied. The potentially functional BST2 variants were selected through a strategy of gene‐wide screening. The associations of BST2 variants and polygenic score (PGS) model, which was used to quantify the combined influence of several genetic variants, with treatment response were examined in 2 separate PegIFNα‐treated cohorts of 238 and 707 patients with CHB, respectively. We found that overexpression of BST2 improved the anti‐HBV activity triggered by IFN‐α. Among PegIFNα‐treated patients with CHB, BST2 _rs9576 was screened out to be significantly correlated with combined response (CR; i.e., HBeAg seroconversion along with HBV DNA level

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusHepatitis B, ChronicHumansHepatitis B e AntigensHepatitis B Surface AntigensAntiviral AgentsJanus KinasesTreatment OutcomeDNA, ViralSTAT Transcription FactorsSignal TransductionInterferon-alphaPolyethylene GlycolsRecombinant ProteinsBone Marrow Stromal Antigen 2

Substanzen

Hepatitis B e AntigensHepatitis B Surface AntigensAntiviral AgentsJanus KinasesDNA, ViralSTAT Transcription FactorsInterferon-alphaPolyethylene GlycolsRecombinant ProteinsBST2 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, South…
  • The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
  • Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

ORCID-Profile: Jiaxuan Chen, Jia Hou, Rong Na, Bin Zhou, Jinlin Hou, De-Ke Jiang

Zitieren

APA

Chen, J., Hou, J., Na, R., Zhou, B., Hou, J., & Jiang, D. K. (2024). Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN ‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg ‐Positive Chronic Hepatitis B Patients. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3120

Vancouver

Chen J, Hou J, Na R, Zhou B, Hou J, Jiang DK. Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN ‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg ‐Positive Chronic Hepatitis B Patients. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3120

BibTeX
@article{Chen2024,
  author = {Chen, Jiaxuan and Hou, Jia and Na, Rong and Zhou, Bin and Hou, Jinlin and Jiang, De-Ke},
  title = {Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN ‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg ‐Positive Chronic Hepatitis B Patients},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3120}
}
Kostenlos starten →